A Phase I Dose-Escalation Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC 747691) Plus Pan-Notch Inhibitor RO4929097 (NSC 749225) Administered in Patients With Advanced Breast Cancer.

Trial Profile

A Phase I Dose-Escalation Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC 747691) Plus Pan-Notch Inhibitor RO4929097 (NSC 749225) Administered in Patients With Advanced Breast Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2015

At a glance

  • Drugs RG 4733 (Primary) ; Vismodegib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Apr 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 24 Jan 2014 Status changed from recruiting to active, no longer recruiting; according to CLinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top